Administration of dasatinib at a low dose (5 mg/kg) had no effect on tumor growth (Fig. 3c and Supplementary Fig. S2g), but it drastically decreased the luminescence intensity of CD63-Antares2 cells in both the blood and homing organs in a dose-dependent manner (Fig. 3d,e). This evidence concerns the gene CD63 and neoplasm.